Muhammad Dayyab Farouq, Iliyasu Garba, Garba Ahmad Bashir, Aliyu Umar Ibrahim, Musa Shuaib Nura, Bajehson Mamman, Muhammad Daiyab Ibrahim, Akpala Oji, Remilekun Olaoye, Garba Habib Abdulrazaq
Infectious Disease Hospital, Kano, Nigeria.
Department of Medicine, College of Health Sciences, Bayero University, Kano, Nigeria.
J Clin Tuberc Other Mycobact Dis. 2022 May 17;28:100319. doi: 10.1016/j.jctube.2022.100319. eCollection 2022 Aug.
with resistance to first line and second line anti tuberculous drugs is a serious setback in the treatment of tuberculosis (TB). The COVID-19 pandemic constitutes a serious threat that could unwind the recent gains made thus far in the control of tuberculosis. This study aims to explore the pattern of drug resistant tuberculosis (DRTB) in our institution. We also aimed to explore the changing trends of TB in the era of the COVID-19 pandemic.
This descriptive study included all DRTB patients admitted and managed in the hospital between January 2018 and December 2020. We compare TB case detection in the facility before and after COVID-19 pandemic. Drug susceptibility testing were expressed as frequencies and percentages.
The study found that there was 66.03%, 45.09% and 77.78% drop in case detection of drug-sensitive TB (DSTB), DRTB and Fluoroquinolone (FQ) resistant TB respectively in the year 2020 compared to 2019. The drop in cases was similar when the year 2020 was compared to 2018. Among the 132 patients in the cohort, resistance to isoniazid, fluoroquinolones and second-line injectable agents were reported as 23.48%, 12.88%, and 31.06% respectively.
We question the potential reason why a drop in tuberculosis cases was observed in the year 2020 and we alert the Nigerian authorities that COVID-19 control efforts going hand-in-hand with intensified TB case finding and surveillance efforts and initiating proper TB treatment for persons with active TB are urgently needed.
对一线和二线抗结核药物产生耐药性是结核病治疗中的一个严重挫折。新冠疫情构成了严重威胁，可能会使迄今为止在结核病控制方面取得的近期成果付诸东流。本研究旨在探讨我院耐药结核病（DRTB）的模式。我们还旨在探讨新冠疫情时代结核病的变化趋势。
这项描述性研究纳入了2018年1月至2020年12月期间在我院住院并接受治疗的所有DRTB患者。我们比较了新冠疫情前后该机构的结核病病例发现情况。药物敏感性测试结果以频率和百分比表示。
研究发现，与2019年相比，2020年药物敏感结核病（DSTB）、DRTB和耐氟喹诺酮（FQ）结核病的病例发现率分别下降了66.03%、45.09%和77.78%。与2018年相比，2020年病例下降情况相似。在该队列的132名患者中，对异烟肼、氟喹诺酮类和二线注射剂的耐药率分别报告为23.48%、12.88%和31.06%。
我们对2020年结核病病例下降的潜在原因提出质疑，并提醒尼日利亚当局，迫切需要将新冠疫情防控工作与加强结核病病例发现和监测工作相结合，并为活动性结核病患者启动适当的结核病治疗。
